{"id":12550,"date":"2025-04-09T09:57:40","date_gmt":"2025-04-09T16:57:40","guid":{"rendered":"https:\/\/www.qad.com\/blog\/?p=12550"},"modified":"2025-04-09T09:57:40","modified_gmt":"2025-04-09T16:57:40","slug":"how-to-mitigate-and-manage-supply-chain-disruptions-in-life-sciences","status":"publish","type":"post","link":"https:\/\/www.qad.com\/blog\/2025\/04\/how-to-mitigate-and-manage-supply-chain-disruptions-in-life-sciences","title":{"rendered":"How to Mitigate and Manage Supply Chain Disruptions in Life Sciences"},"content":{"rendered":"

[vc_row][vc_column][vc_single_image image=”12551″ img_size=”full”][vc_column_text]<\/p>\n

Can You Prevent Supply Chain Disruptions in Life Sciences?<\/span><\/h2>\n

Supply chain disruptions in the life sciences industry can have serious consequences. While it\u2019s impossible to eliminate all risks, companies and the industry at large can take proactive steps to minimize disruptions and improve supply chain resilience.<\/span><\/p>\n

The Biggest Supply Chain Challenges in Life Sciences<\/span><\/h2>\n

The biggest supply chain challenges for life sciences are:<\/span><\/p>\n

    \n
  1. Raw material and component shortages<\/span><\/li>\n
  2. Demand volatility and Over-Reliance on Few Suppliers<\/span><\/li>\n
  3. Regulatory and Trade Requirements<\/span><\/li>\n
  4. Economic and Policy Volatility<\/span><\/li>\n<\/ol>\n

    Material Shortages and Long Lead Times in Pharmaceuticals<\/span><\/h3>\n

    Global raw material shortages and extended lead times for critical components create bottlenecks for drug and medical device manufacturers, impacting production schedules and patient access to vital treatments. This is compounded by the fact that many raw materials are sourced from a limited number of suppliers and regions. Beyond the well-documented API sourcing problems, shortages in excipients, packaging materials (including vials and syringes), and electronic components for medical devices also contribute to delays.<\/span><\/p>\n

    To mitigate the impact of material shortages and long lead times in pharmaceuticals, life sciences companies must adopt a multi-faceted approach. This includes strategic dual sourcing and regionalization, implementing optimized inventory buffers, engaging in early supplier involvement, and establishing contractual agreements with clear lead time clauses. Leveraging technology for real-time tracking and exploring material substitutions are also crucial. Proactive communication and agile manufacturing further enhance resilience. By implementing these strategies, companies can better navigate supply chain disruptions.\u00a0<\/span><\/p>\n

    Here are areas of opportunity that look at the hidden costs and visibility challenges life sciences today:<\/span><\/p>\n

    Demand Volatility and Over-Reliance on Few Suppliers<\/span><\/h3>\n

    Reliance on active pharmaceutical ingredients (APIs) manufacturers concentrated in regions such as China and India exposes pharmaceutical companies to significant geopolitical risks. This is a sobering reality for countries like the US, where <\/span>91% of all prescriptions are for generic drugs<\/span><\/a>, with 83 of the 100 most used generic medicines having no domestic source for their ingredients.\u00a0<\/span><\/p>\n

    Fluctuating demand for life-saving drugs can strain production capacity and inventory levels. Balancing inventory to avoid stock-outs against maintaining too much safety stock is especially a challenge. Miscalculations regarding the amounts and locations of inventory and raw materials needed present one of the most significant risks to a life science firm\u2019s profitability.<\/span><\/p>\n

    Regulatory and Trade Compliance Barriers<\/span><\/h3>\n

    Strict regulatory requirements for pharmaceuticals and medical devices imposed in various regions add complexity to global supply chains. Tariffs varying by country, export controls, and evolving compliance rules and restricted zones create additional hurdles for manufacturers.\u00a0<\/span><\/p>\n

    Economic and Policy Volatility<\/span><\/h3>\n

    The impact of trade wars, political unrest between nations, and policy upheavals will ultimately be reflected in a company\u2019s profit margin. Inflation driving higher costs of materials and geographic concentration of sources of needed materials make the financial status of life sciences companies particularly vulnerable to economic volatility. Policies related to trade agreements can be in flux, adding more complexity when adding additional sources to strengthen supply chain resiliency.<\/span><\/p>\n

    The Hidden Costs of Supply Chain Disruptions: Symptoms to Watch<\/span><\/h3>\n

    Clues that a supply chain is under pressure are many. Trends to watch in the following areas can serve as early warning signs \u2013 as well as be the result of a supply chain already under pressure and experiencing bottlenecks:<\/span><\/p>\n

    Increased shipping costs:<\/b> Unexpected disruptions may alter trade routes causing shipping costs to rise. P<\/span>harmaceuticals and biologic products, which have highly specific handling requirements such as maintaining temperature and humidity to avoid product spoilage, have the added burden of ensuring maintenance of these conditions throughout modified routes which may have longer delivery times and even higher transport costs.<\/span><\/p>\n

    Production halts and idle capacity:<\/b> Not assessing potential risk in advance of disruptions to the flow of components or material\u00a0 alternative sources can lead to work stoppage and financial loss.<\/span><\/p>\n

    Regulatory fines and compliance issues:<\/b> Not having an efficient way to screen, onboard, and routinely monitor performance of suppliers as you increase the number of suppliers to mitigate the impact of future supply chain disruption occurring with a single supplier or region, can cause delays in discovering and identifying compliance and quality issues. This can lead to financial loss due to fines, expensive recalls, and reputation damage.<\/span><\/p>\n

    Poor Supply Chain Visibility and the Lack of Real-Time Data<\/span><\/h3>\n

    Limited end-to-end visibility makes it difficult to anticipate and react to disruptions. Lack of real-time tracking and analytics gaps can hinder proactive decision making. According to a <\/span>Gartner study<\/span><\/a>, 77% of companies stated that their supply chains give them a competitive advantage, but the percentage drops to 69% in life sciences. The life sciences industry has work to do to catch up to other industries in addressing challenges and achieving competitive advantage.<\/span><\/p>\n

    Inefficient Inventory Management and Forecasting<\/span><\/h3>\n

    Inaccurate <\/span>demand forecasting<\/span><\/a> leads to stock shortages or overproduction. Inefficient inventory tracking causes supply imbalances and waste. Demand forecasting becomes especially crucial during times of great demand volatility.<\/span><\/p>\n

    Proven Strategies to Strengthen Life Sciences Supply Chains<\/span><\/h2>\n

    Increasing end-to-end visibility of the supply chain is the number one way to significantly enhance the resiliency of the supply chain. What can\u2019t be seen, can\u2019t be managed.\u00a0<\/span><\/p>\n

    Here are two hacks that life sciences firms can use to significantly strengthen their supply chains and reap benefits in a relatively short time:<\/span><\/p>\n

      \n
    1. Adopt digital tools to address demand volatility, and better manage inventory costs.<\/b> QAD Digital Supply Chain Planning<\/span><\/a> will more rapidly and more accurately help life sciences companies understand future demand, balance supply with demand, and boost supply chain resilience. It incorporates intelligent algorithmic methods and machine learning that can be applied to improve accuracy downstream to improve visibility \u2013 and profitability.<\/span><\/li>\n
    2. Diversify suppliers and improve collaboration to build stronger and more agile networks.<\/b> Communication and collaboration with suppliers is absolutely critical in the current environment. Make it easier to onboard and communicate with new suppliers as you expand and diversify your supplier network using digital <\/span>QAD Supplier Management tools<\/span><\/a>. Use QAD\u2019s <\/span>\u201c24 Essential Supply Chain Processes\u201d<\/span><\/a> as a guide and request a supply chain assessment.<\/span><\/li>\n<\/ol>\n

      At the industry level, transitioning from reliance on a global, interconnected network of suppliers to development of more local sources may not happen overnight, however, there are initiatives to support the creation of local sources and \u201cnear-shoring\u201d. Collaborate with organizations leading industry initiatives and conferences supporting life sciences and general supply chain resiliency, and the development of local sources. <\/span>Here are a few to explore:<\/span><\/p>\n

      International<\/b><\/p>\n